{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274069","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.976241+00:00","generated_at":"2026-06-08T06:53:54.300960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verrica posts Q3 2023 net loss of $24.8M; first YCANTH revenue $2.8M","bullets":["First commercial YCANTH sale to distributor FFF generated $2.8M product revenue; net loss $24.8M ($0.54/share).","Non-GAAP net loss $14.8M ($0.32/share) vs. non-GAAP net income $2.9M in Q3 2022.","SG&A surged to $20.1M (from $3.9M) due to YCANTH commercial ramp and $7.4M stock compensation.","Over 112M lives covered by commercial/managed Medicaid; fee-for-service Medicaid in 4 states.","Cash $84.3M; closed $125M OrbiMed debt facility ($50M drawn) to fund operations into Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274069","json":"https://secwatch.observer/filing/0001193125-23-274069.json","markdown":"https://secwatch.observer/filing/0001193125-23-274069.md","text":"https://secwatch.observer/filing/0001193125-23-274069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/0001193125-23-274069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/d280768d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:53:54.300960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91dc9af62335fbae914448f712b4b7c68fc0ab03","claim":"Verrica Pharmaceuticals Inc. reported third quarter ended September 30, 2023 results: revenue $2.8 million.","evidence_excerpt":"24, 2023 we received our first commercial sale of YCANTH TM to our exclusive distributor, FFF Enterprises Inc., resulting in net product revenue for the third quarter 2023 of $2.8 million upon its delivery to FFF. This first sale to FFF primarily represented stocking within the channel to allow patients to finally gain access to the first FDA-approved therapy for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523274069/0001193125-23-274069-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}